Author

Giorgia Risi

Institute of Oncology Research

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Organism:human· 1 Organism:mouse· 1 Research Focus:perturbation response prediction· 1

Frequent Co-Authors

Chiara TarantelliiD· 2 shared Elisa CivanelliiD· 2 shared Filippo SprianoiD· 2 shared Francesco BertoniiD· 2 shared Luciano CascioneiD· 2 shared Alberto J. ArribasiD· 1 shared Anastasios StathisiD· 1 shared Eleonora CannasiD· 1 shared

Activity by Year

2025-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 41 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Chiara TarantelliORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Characterization of lymphoma models for the surface ROR1 expression

Chiara Tarantelli, Elisa Civanelli, Filippo Spriano, Giorgia Risi, Luciano Cascione, Gunnar F. Kaufmann, Francesco Bertoni

The paper characterizes ROR1 expression in B-cell lymphoma models and shows that ROR1-positive models are sensitive to a ROR1-targeting ADC.

bioRxiv · Nov 19, 2025 · PreprintCancer Biology

The anti-metabolite KAT/3BP has in vitro and in vivo anti-tumor activity in lymphoma models

Chiara Tarantelli, Filippo Spriano, Elisa Civanelli, Luca Aresu, Giorgia Risi, Eleonora Cannas, Omar Kayali, Luciano Cascione, Alberto J. Arribas, Anastasios Stathis, Young Hee Ko, Francesco Bertoni

This study evaluates KAT/3BP, a 3BP derivative, showing in vitro and in vivo anti-tumor activity against lymphoma models, including resistant cell lines and synergistic effects with existing therapies.

bioRxiv · Apr 23, 2025 · PreprintCancer Biology